Literature DB >> 24655689

Automatic optimization of cardiac resynchronization therapy using SonR-rationale and design of the clinical trial of the SonRtip lead and automatic AV-VV optimization algorithm in the paradym RF SonR CRT-D (RESPOND CRT) trial.

Josep Brugada1, Johannes Brachmann2, Peter Paul Delnoy3, Luigi Padeletti4, Dwight Reynolds5, Philippe Ritter6, Alberto Borri-Brunetto7, Jagmeet P Singh8.   

Abstract

Although cardiac resynchronization therapy (CRT) is effective in most patients with heart failure (HF) and ventricular dyssynchrony, a significant minority of patients (approximately 30%) are non-responders. Optimal atrioventricular and interventricular delays often change over time and reprogramming these intervals might increase CRT effectiveness. The SonR algorithm automatically optimizes atrioventricular and interventricular intervals each week using an accelerometer to measure change in the SonR signal, which was shown previously to correlate with hemodynamic improvement (left ventricular [LV] dP/dtmax). The RESPOND CRT trial will evaluate the effectiveness and safety of the SonR optimization system in patients with HF New York Heart Association class III or ambulatory IV eligible for a CRT-D device. Enrolled patients will be randomized in a 2:1 ratio to either SonR CRT optimization or to a control arm employing echocardiographic optimization. All patients will be followed for at least 24 months in a double-blinded fashion. The primary effectiveness end point will be evaluated for non-inferiority, with a nested test of superiority, based on the proportion of responders (defined as alive, free from HF-related events, with improvements in New York Heart Association class or improvement in Kansas City Cardiomyopathy Questionnaire quality of life score) at 12 months. The required sample size is 876 patients. The two primary safety end points are acute and chronic SonR lead-related complication rates, respectively. Secondary end points include proportion of patients free from death or HF hospitalization, proportion of patients worsened, and lead electrical performance, assessed at 12 months. The RESPOND CRT trial will also examine associated reverse remodeling at 1 year.
Copyright © 2014 The Authors. Published by Mosby, Inc. All rights reserved.

Entities:  

Mesh:

Year:  2013        PMID: 24655689     DOI: 10.1016/j.ahj.2013.12.007

Source DB:  PubMed          Journal:  Am Heart J        ISSN: 0002-8703            Impact factor:   4.749


  11 in total

Review 1.  Cardiac resynchronization therapy: history, present status, and future directions.

Authors:  Leeor M Jaffe; Daniel P Morin
Journal:  Ochsner J       Date:  2014

2.  Cardiac resynchronization therapy update: evolving indications, expanding benefit?

Authors:  C Butcher; Y Mareev; V Markides; M Mason; T Wong; J G F Cleland
Journal:  Curr Cardiol Rep       Date:  2015-10       Impact factor: 2.931

Review 3.  Recent advances in the optimization of cardiac resynchronization therapy.

Authors:  Satish Chandraprakasam; Gina G Mentzer
Journal:  Curr Heart Fail Rep       Date:  2015-02

Review 4.  Clinical Relevance Of Systematic CRT Device Optimization.

Authors:  Maurizio Lunati; Giovanni Magenta; Giuseppe Cattafi; Antonella Moreo; Giacomo Falaschi; Danilo Contardi; Emanuela Locati
Journal:  J Atr Fibrillation       Date:  2014-08-31

5.  Developments in Cardiac Resynchronisation Therapy.

Authors:  Geoffrey F Lewis; Michael R Gold
Journal:  Arrhythm Electrophysiol Rev       Date:  2015-08

6.  The clinical benefit of cardiac resynchronization therapy optimization using a device-based hemodynamic sensor in a patient with dilated cardiomyopathy: a case report.

Authors:  Mario Volpicelli; Gregorio Covino; Paolo Capogrosso
Journal:  J Med Case Rep       Date:  2015-12-19

7.  First clinical evaluation of an atrial haemodynamic sensor lead for automatic optimization of cardiac resynchronization therapy.

Authors:  David Duncker; Peter Paul Delnoy; Herbert Nägele; Jacques Mansourati; Lluís Mont; Frédéric Anselme; Petra Stengel; Francesca Anselmi; Hanno Oswald; Christophe Leclercq
Journal:  Europace       Date:  2015-05-14       Impact factor: 5.214

8.  The future of telemedicine for the management of heart failure patients: a Consensus Document of the Italian Association of Hospital Cardiologists (A.N.M.C.O), the Italian Society of Cardiology (S.I.C.) and the Italian Society for Telemedicine and eHealth (Digital S.I.T.).

Authors:  Andrea Di Lenarda; Giancarlo Casolo; Michele Massimo Gulizia; Nadia Aspromonte; Simonetta Scalvini; Andrea Mortara; Gianfranco Alunni; Renato Pietro Ricci; Roberto Mantovan; Giancarmine Russo; Gian Franco Gensini; Francesco Romeo
Journal:  Eur Heart J Suppl       Date:  2017-05-02       Impact factor: 1.803

9.  Evaluation of the therapeutic effects of QuickOpt optimization in Chinese patients with chronic heart failure treated by cardiac resynchronization.

Authors:  Ji Yan; Shu Zhang; Dejia Huang; Xiaolin Xue; Jing Xu; Qianmin Tao; Weize Zhang; Zheng Zhang; Wei Hua; Yanchun Liang; Baopeng Tang; Wei Xu; Geng Xu; Xuejun Ren; Jingfeng Wang; Tao Guo; Shaobin Jia; Yugang Dong; Hong Jiang; Guosheng Fu; Liguang Zhu; Lin Chen; Fuli Tian; Feng Ling; Jianmei Li; Xiaoyong Qi; Yinglu Hao; Yutang Wang; Liangrong Zheng; Xiaoqun Pu; Farong Shen; Guangping Li; Hui Li; Fang Peng
Journal:  Sci Rep       Date:  2018-03-09       Impact factor: 4.379

10.  Contractility sensor-guided optimization of cardiac resynchronization therapy: results from the RESPOND-CRT trial.

Authors:  Josep Brugada; Peter Paul Delnoy; Johannes Brachmann; Dwight Reynolds; Luigi Padeletti; Georg Noelker; Charan Kantipudi; José Manuel Rubin Lopez; Wolfgang Dichtl; Alberto Borri-Brunetto; Luc Verhees; Philippe Ritter; Jagmeet P Singh
Journal:  Eur Heart J       Date:  2017-03-07       Impact factor: 29.983

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.